BioCentury
ARTICLE | Company News

Biovail, Cambridge Laboratories, GlaxoSmithKline sales and marketing update

May 25, 2009 7:00 AM UTC

Biovail will acquire worldwide rights to a portfolio of tetrabenazine products from Cambridge for $200 million up front, plus $30 million in two tranches over two years. The deal includes Xenazine/ Nitoman tetrabenazine, tetrabenazine CR ( BVF-018) and RUS350. Biovail already markets tetrabenazine as Nitoman in Canada to treat hyperkinetic movement disorders and receives royalties from its marketing partner in the U.S., H. Lundbeck A/S (CSE:LUN, Copenhagen, Denmark). The selective inhibitor of vesicular monoamine transporter 2 (VMAT2) also is approved in Australia, France, Germany, Ireland and the U.K. Tetrabenazine CR and RUS350, an isomer of tetrabenazine, are expected to start Phase II testing to treat Tourette's syndrome and an undisclosed indication, respectively, in 1H10. The deal is expected to close within 90 days.

Biovail gained Canadian rights to Nitoman from its acquisition of Prestwick Pharmaceuticals Inc. last year (see BioCentury, Sept. 22, 2008). ...